Oncotarget

Research Papers:

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo

Moran Mazuz, Amir Tiroler, Lilach Moyal, Emmilia Hodak, Stalin Nadarajan, Ajjampura C. Vinayaka, Batia Gorovitz-Haris, Ido Lubin, Avi Drori, Guy Drori, Owen Van Cauwenberghe, Adi Faigenboim, Dvora Namdar, Iris Amitay-Laish and Hinanit Koltai _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2020; 11:1141-1156. https://doi.org/10.18632/oncotarget.27528

Metrics: PDF 599 views  |   Full Text 2367 views  |   ?  


Abstract

Moran Mazuz1,*, Amir Tiroler1,2,*, Lilach Moyal3,4, Emmilia Hodak3,4, Stalin Nadarajan1, Ajjampura C. Vinayaka1, Batia Gorovitz-Haris4, Ido Lubin5, Avi Drori6, Guy Drori6, Owen Van Cauwenberghe7, Adi Faigenboim1, Dvora Namdar1, Iris Amitay-Laish3,4,# and Hinanit Koltai1,#

1 Agricultural Research Organization (ARO), Volcani Center, Rishon LeZion, Israel

2 The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel

3 Division of Dermatology, Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

4 Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

5 Core Facility, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

6 MedC Biopharma Corporation, Ontario, Canada

7 AgMedica Bioscience Inc., Chatham-Kent, Canada

* These authors equally contributed as the first author

# These authors equally contributed as the last author

Correspondence to:

Hinanit Koltai,email: hkoltai@agri.gov.il

Keywords: cutaneous T-cell lymphoma; cannabis; cannabinoids; peripheral blood lymphocytes; CTCL cell lines

Received: July 15, 2019     Accepted: March 03, 2020     Published: March 31, 2020

ABSTRACT

Cannabis sativa produces hundreds of phytocannabinoids and terpenes. Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), characterized by patches, plaques and tumors. Sézary is a leukemic stage of CTCL presenting with erythroderma and the presence of neoplastic Sézary T-cells in peripheral blood. This study aimed to identify active compounds from whole cannabis extracts and their synergistic mixtures, and to assess respective cytotoxic activity against CTCL cells. Ethanol extracts of C. sativa were analyzed by high-performance liquid chromatography (HPLC) and gas chromatography/mass spectrometry (GC/MS). Cytotoxic activity was determined using the XTT assay on My-La and HuT-78 cell lines as well as peripheral blood lymphocytes from Sézary patients (SPBL). Annexin V assay and fluorescence-activated cell sorting (FACS) were used to determine apoptosis and cell cycle. RNA sequencing and quantitative PCR were used to determine gene expression. Active cannabis compounds presenting high cytotoxic activity on My-La and HuT-78 cell lines were identified in crude extract fractions designated S4 and S5, and their synergistic mixture was specified. This mixture induced cell cycle arrest and cell apoptosis; a relatively selective apoptosis was also recorded on the malignant CD4+CD26- SPBL cells. Significant cytotoxic activity of the corresponding mixture of pure phytocannabinoids further verified genuine interaction between S4 and S5. The gene expression profile was distinct in My-La and HuT-78 cells treated with the S4 and S5 synergistic mixture. We suggest that specifying formulations of synergistic active cannabis compounds and unraveling their modes of action may lead to new cannabis-based therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27528